Anlon Healthcare Limited has submitted its quarterly monitoring agency report for Q3FY26 to stock exchanges, demonstrating continued progress in IPO fund utilization under regulatory oversight. The pharmaceutical company, which raised ₹12,103.00 lakh through its public issue, reported utilizing ₹9,579.04 lakh of the proceeds as of December 31, 2025.

Regulatory Compliance and Monitoring Framework

Pursuant to Regulation 30 and 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Regulation 41(2) of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, the company submitted the monitoring agency report issued by CRISIL Ratings Limited on February 10, 2026. The report covers the quarter and nine months ended December 31, 2025.

IPO Fund Utilization Progress

The monitoring report reveals systematic deployment of IPO proceeds across stated objectives, with no deviations from the original prospectus disclosures. The company has maintained transparency in fund utilization while progressing on expansion plans.

Object-wise Fund Deployment

The company has made significant progress across all stated objectives, with complete utilization in debt repayment and working capital requirements.

The company utilized ₹1,333.59 lakh during Q3FY26, with ₹853.59 lakh deployed for general corporate purposes toward meeting expenses incurred in ordinary business operations.

Unutilized Funds Management

The remaining ₹2,523.96 lakh has been strategically deployed in fixed deposits and current accounts to ensure optimal returns while maintaining liquidity for ongoing projects.

Compliance and Governance Highlights

The monitoring agency confirmed no deviations from stated objectives and no material changes in financing arrangements. The company has obtained Consent to Establishment (CTE) approval for its expansion project, with other statutory approvals in progress. CRISIL Ratings noted that vendor arrangements have been modified compared to prospectus disclosures, but these changes align with the flexibility provisions outlined in the original offer document.

The Board of Directors ratified and approved the utilization of proceeds under General Corporate Purposes through a resolution dated February 09, 2026, ensuring proper governance oversight of fund deployment.

Anlon healthcare Limited has notified stock exchanges about new product development and the positive impact of the recently signed India-European Union trade agreement on its business operations. The company submitted its disclosure to BSE and NSE on January 28, 2026, in compliance with Regulation 30 of SEBI Listing Regulations.

Trade Agreement Impact

The Government of India and the European Union have signed a comprehensive trade agreement designed to enhance trade and investment between the two regions. According to the company's filing, this agreement is expected to have a positive impact on Anlon Healthcare's operations.

European Market Presence

Anlon Healthcare has already established its presence in the European market by exporting one of its key products to Italy and Germany. This existing footprint in European Union countries positions the company to potentially benefit from the enhanced trade relationship established through the new agreement.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was signed by Punitkumar Rasadia, Managing Director with DIN 06696258.

The company requested both stock exchanges to take the information on record as part of its ongoing disclosure obligations to keep investors informed about material developments.